These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 21395337)
1. Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. Li L; Crow D; Turatti F; Bading JR; Anderson AL; Poku E; Yazaki PJ; Carmichael J; Leong D; Wheatcroft D; Raubitschek AA; Hudson PJ; Colcher D; Shively JE Bioconjug Chem; 2011 Apr; 22(4):709-16. PubMed ID: 21395337 [TBL] [Abstract][Full Text] [Related]
2. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. Li L; Turatti F; Crow D; Bading JR; Anderson AL; Poku E; Yazaki PJ; Williams LE; Tamvakis D; Sanders P; Leong D; Raubitschek A; Hudson PJ; Colcher D; Shively JE J Nucl Med; 2010 Jul; 51(7):1139-46. PubMed ID: 20554731 [TBL] [Abstract][Full Text] [Related]
3. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Li L; Yazaki PJ; Anderson AL; Crow D; Colcher D; Wu AM; Williams LE; Wong JY; Raubitschek A; Shively JE Bioconjug Chem; 2006; 17(1):68-76. PubMed ID: 16417253 [TBL] [Abstract][Full Text] [Related]
4. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Li L; Olafsen T; Anderson AL; Wu A; Raubitschek AA; Shively JE Bioconjug Chem; 2002; 13(5):985-95. PubMed ID: 12236780 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model. Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151 [TBL] [Abstract][Full Text] [Related]
6. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848 [TBL] [Abstract][Full Text] [Related]
7. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport. Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224 [TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of α White JB; Hu LY; Boucher DL; Sutcliffe JL Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240 [TBL] [Abstract][Full Text] [Related]
9. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related]
10. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Shi J; Kim YS; Zhai S; Liu Z; Chen X; Liu S Bioconjug Chem; 2009 Apr; 20(4):750-9. PubMed ID: 19320477 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048 [TBL] [Abstract][Full Text] [Related]
12. Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody. White JB; Boucher DL; Zettlitz KA; Wu AM; Sutcliffe JL Nucl Med Biol; 2015 Dec; 42(12):945-57. PubMed ID: 26341848 [TBL] [Abstract][Full Text] [Related]
13. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683 [TBL] [Abstract][Full Text] [Related]
14. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969 [TBL] [Abstract][Full Text] [Related]
17. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724 [TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420 [TBL] [Abstract][Full Text] [Related]